IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation
This study is ongoing, but not recruiting participants.
Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
National Comprehensive Cancer Network
Novartis
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01682213
First received: September 6, 2012
Last updated: June 12, 2017
Last verified: June 2017
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is ongoing, but not recruiting participants. |
|---|---|
| Estimated Study Completion Date: | September 2018 |
| Estimated Primary Completion Date: | September 2018 (Final data collection date for primary outcome measure) |